Researchers have developed a new methodology that uses artificial intelligence tools to identify and count target viruses ...

The world population is suffering a lot of genetic diseases. These diseases have been very hard to tackle so far. Fortunately, since a few decades viral vectors and gene therapies became more and more ...

Researchers have developed a new methodology that uses artificial intelligence (AI) tools to identify and count target viruses more efficiently than previous techniques. The new approach can be used ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.